Phase 2Not yet recruitingPriority 3 · Moderate priorityNCT07347288
SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma
Plain-language summary
This trial is testing SHR2554 Tablets for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
SHR2554 Tablets (DRUG): SHR2554 orally twice daily
SHR2554 Tablets
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details